Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.

Clin Infect Dis · 2023 · PMC10150276 · PMID 37125467

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Most notably, however, the 28-day mortality rates showed a trend towards lower mortality among patients who received sulbactam-durlobactam (19% [12/63]) compared with colistin (32% [20/62]) (95% CI: –30.0% to 3.5%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.